Department of Neonatology, Catholic University of the Sacred Heart, Rome, Italy.
Department of Radiology, Catholic University of the Sacred Heart, Rome, Italy.
Pediatr Pulmonol. 2018 Sep;53(9):1231-1236. doi: 10.1002/ppul.24076. Epub 2018 Jun 5.
We aim to verify the diagnostic accuracy of a lung ultrasonography (LUS) score to early predict the need for surfactant therapy in newborns with respiratory distress syndrome (RDS), and to compare it with a chest X-ray score.
In this prospective diagnostic accuracy study we included all newborns admitted for respiratory distress and initially treated with nasal CPAP. LUS was performed within 2 h from nasal CPAP positioning and in any case before surfactant administration. A chest X-ray was also performed. A LUS score and an X-ray score were used and compared. Ability of the scores to predict surfactant administration was evaluated through ROC analysis.
In our population of 56 newborns with mean gestational age of 31 weeks (SD 3) and mean birth weight of 1442 g (SD 520), LUS score showed higher AUC than X-ray score in early recognition of infants with respiratory distress syndrome requiring surfactant treatment (0.94; 95%CI, 0.89-0.98; P < 0.001 vs 0.80; 95%CI, 0.74-0.86; P < 0.001). It showed also higher sensitivity (86% vs 82%), higher specificity (88% vs 76%), better positive (83% vs 69%), and negative (91% vs 87%) predictive values.
LUS is a non-invasive, bedside and reproducible method that could improve the management of neonatal respiratory distress. It is accurate and reliable to early identify patients who will need treatment with surfactant allowing both an early treatment and a reduction of radiation exposure.
我们旨在验证肺部超声(LUS)评分预测新生儿呼吸窘迫综合征(RDS)患儿需用肺表面活性物质治疗的诊断准确性,并与胸部 X 线评分进行比较。
本前瞻性诊断准确性研究纳入了所有因呼吸窘迫而入院且最初接受经鼻持续气道正压通气(nCPAP)治疗的新生儿。LUS 在 nCPAP 定位后 2 小时内进行,且在任何情况下均在肺表面活性物质给药前进行。还进行了胸部 X 线检查。使用并比较了 LUS 评分和 X 线评分。通过 ROC 分析评估评分预测肺表面活性物质给药的能力。
在我们的 56 例新生儿中,平均胎龄为 31 周(标准差 3),平均出生体重为 1442 克(标准差 520 克),LUS 评分在早期识别需要肺表面活性物质治疗的 RDS 患儿方面显示出高于 X 线评分的 AUC(0.94;95%CI,0.89-0.98;P<0.001 与 0.80;95%CI,0.74-0.86;P<0.001)。它还显示出更高的敏感性(86% 与 82%)、更高的特异性(88% 与 76%)、更好的阳性预测值(83% 与 69%)和阴性预测值(91% 与 87%)。
LUS 是一种非侵入性、床边和可重复的方法,可以改善新生儿呼吸窘迫的管理。它可以准确可靠地早期识别需要用肺表面活性物质治疗的患者,从而实现早期治疗并减少辐射暴露。